$173 Million

ImmunoGen, Inc.

Follow-on Offering

Bookrunner, June 2018

ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company focused on developing innovative antibody-drug conjugate, or ADC, therapies that meaningfully improve the lives of people with cancer.